AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Multiple Myeloma Refractory

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 260 sites๐Ÿ“ Huntsville๐Ÿ“ Phoenix๐Ÿ“ Scottsdale C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Dexamethasone Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma NCT05896228Phase 21 site๐Ÿ“ Miami Benjamin T Diamond, MD ยท Tests: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen Universal CAR-T Cell Therapy for MM NCT07248176NA1 site๐Ÿ“ Shanghai Bioray Laboratories ยท Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma NCT07772024Phase 31 site๐Ÿ“ Miami CellCentric Ltd. ยท Tests: InoPd, Investigator's choice of SAT A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites๐Ÿ“ Bullhead City๐Ÿ“ Los Angeles๐Ÿ“ Pembroke Pines GlaxoSmithKline ยท Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma NCT07760454Phase 1, Phase 22 sites๐Ÿ“ Suzhou๐Ÿ“ Shanghai UCARsgen Biotech Limited ยท Tests: CT0596 A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310Phase 11 site๐Ÿ“ West Hollywood Oncotherapeutics ยท Tests: Selinexor, Ruxolitinib, Methylprednisolone A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252Phase 11 site๐Ÿ“ Atlanta OriCell Therapeutics Co., Ltd. ยท Tests: OriCAR-017 Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma NCT07333430Phase 11 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Naive HBI0101 CAR-T Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044Phase 116 sites๐Ÿ“ Phoenix๐Ÿ“ Orange๐Ÿ“ Jacksonville Jiangsu Simcere Pharmaceutical Co., Ltd. ยท Tests: SIM0500 A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma NCT07589634Phase 238 sites๐Ÿ“ Goodyear๐Ÿ“ Beverly Hills๐Ÿ“ Irvine Janssen Research & Development, LLC ยท Tests: Ramantamig, Tocilizumab, Placebo Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) NCT05862012Phase 132 sites๐Ÿ“ Palo Alto๐Ÿ“ Miami๐Ÿ“ Atlanta Ichnos Sciences SA ยท Tests: ISB 2001, ISB 2001 A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. NCT06232096Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Mabworks Biotech Co., Ltd. ยท Tests: MBS314 Injection A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites๐Ÿ“ Denver๐Ÿ“ Denver๐Ÿ“ Columbia SCRI Development Innovations, LLC ยท Tests: Elranatamab, Tocilizumab A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials NCT06285318n/a68 sites๐Ÿ“ Aalborg๐Ÿ“ Aarhus N๐Ÿ“ Copenhagen Janssen-Cilag Ltd. ยท Tests: Teclistamab, Talquetamab Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) NCT07200089Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: NT-I7, Placebo Plan Development for Giving Teclistamab in the Outpatient Setting NCT06251076Phase 41 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Teclistamab, Tocilizumab A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma NCT07105059Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Teclistamab, Mezigdomide Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites๐Ÿ“ Tucson๐Ÿ“ Denver๐Ÿ“ Denver SCRI Development Innovations, LLC ยท Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma NCT07454187Phase 1, Phase 24 sites๐Ÿ“ Zhengzhou๐Ÿ“ Suzhou๐Ÿ“ Xiโ€™an Hangzhou Sumgen Biotech Co., Ltd. ยท Tests: SG2918 Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma NCT05853965Phase 1, Phase 25 sites๐Ÿ“ Hamburg๐Ÿ“ Chemnitz๐Ÿ“ Heidelberg Universitรคtsklinikum Hamburg-Eppendorf ยท Tests: Belantamab mafodotin, Venetoclax A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma NCT06732232EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD20/BCMA CAR-T A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983Phase 312 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Hangzhou Sumgen Biotech Co., Ltd. ยท Tests: SG301 Injection, SG301 placebo, pomalidomide, dexamethasone A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma NCT07609030NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma NCT05976555Phase 11 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: BCMA-TGFฮฒ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFฮฒ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFฮฒ CAR-T cells (1 x 1โ€ฆ A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616Phase 1, Phase 210 sites๐Ÿ“ Birmingham๐Ÿ“ San Francisco๐Ÿ“ Atlanta ModernaTX, Inc. ยท Tests: mRNA-2808 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) NCT06464991Phase 328 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Nanjing IASO Biotechnology Co., Ltd. ยท Tests: Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy